Prescription Demand: Total LINZESS prescription demand in the fourth quarter of 2023 was 50 million LINZESS capsules, a 10% increase compared to the fourth quarter of 2022, per IQVIA. Total ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance. “We made ...

– Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – ...

– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year ...

Irritable bowel syndrome with constipation (IBS-C) is characterized by symptoms such as irregular bowel movements, abdominal pain, and bloating. The U.S. Food and Drug Administration (FDA) has ...

1 Refer to the Reconciliation of GAAP Results to Non-GAAP Financial Measures table and to the Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA table at the end of this press release. Refer ...

The FDA has approved a 72-µg dose of Linzess for adults with chronic idiopathic constipation, which Ironwood and Allergan expect to be available in the first quarter of 2017, the companies announced. ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.S. co-promotion of VIBERZI™ (eluxadoline), Allergan's new ...